

RealRate Inc., 2040 Martin Ave., Santa Clara, CA 95050



RealRate

July 10, 2026


To the CEO
Keros Therapeutics Inc
1050 WALTHAM STREET, SUITE 302
LEXINGTON, MA 02421
USA

Keros Therapeutics Inc TOP Rated in the US Pharmaceutical Ranking

Dear Sir or Madam,

at RealRate we have just published the 2026 US Pharmaceutical ranking. I am happy to inform you that Keros Therapeutics Inc has been TOP Rated at rank 1 out of 178.

Overall, 178 US companies were analyzed with respect to their financial strength. The complete rating is published at <https://www.realrate.ai/rankings>. Your individual rating report, showing your strengths compared to your competitors is attached.



RealRate is an international rating agency based in Santa Clara and Berlin. We use artificial intelligence to create fair and explainable company ratings. Customers highly appreciate the RealRate rating seal: only the strongest companies are able to offer highly attractive and innovative products with top customer services. Billion dollar companies rely on our rating and build trust with their customers.

You too can acquire the RealRate seal and advertise with it. We only reach out to the top-rated companies, like yours and only those may subscribe for our seal. Save a lot of money and effort compared to traditional rating agencies: get a RealRate seal for just \$9,900. Simply sign the attached order form and send it back via email.

Please feel free to book a short video call with me: <https://calendly.com/holger-bartel>


Sincerely,

Dr. Holger Bartel, CEO

RealRate Seal Subscription

RealRate Inc.
2040 Martin Ave., Santa Clara, California 95050, USA
Via email to: holger.bartel@realrate.ai

We subscribe to the Pharmaceutical RealRate rating for Keros Therapeutics Inc. The subscription comprises the annual rating update. The invoice will be sent annually, provided that a TOP rating is achieved again. The subscription can be cancelled by written letter, effective for the following year.



RealRate provides the rating seal as a scalable vector graphic. It can be used without any restrictions by Keros Therapeutics Inc (Customer) for all promotional purposes, i.e. in product brochures, presentations, websites and broadcasting.

Item	2026 US Pharmaceutical RealRate rating seal for Keros Therapeutics Inc
Amount	USD 9,900
Order no.	2026-0001664710

Amounts payable by Customer are exclusive of taxes. Customer is responsible for all his taxes and will pay such amounts invoiced by RealRate.

Billing address


Company name	Full name
Street address	Department
City	Phone number
State / province	Email address
ZIP code	
Country	

Shipping address

The electronic RealRate rating seal and the invoice will be sent to
Delivery email

Keros Therapeutics Inc

Date, location, name



The relative strengths and weaknesses of Keros Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Keros Therapeutics Inc compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 137% points. The greatest weakness of Keros Therapeutics Inc is the variable Research and Development, reducing the Economic Capital Ratio by 14% points.

The company's Economic Capital Ratio, given in the ranking table, is 440%, being 211% points above the market average of 229%.

Input Variable	Value in 1000 USD
Assets, Current	315,434
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	20,414
Liabilities, Non-Current	14,475
Other Assets	18,290
Other Compr. Net Income	0
Other Expenses	4,883
Other Liabilities	0
Other Net Income	24,328
Other Revenues	244,061
Property and Equipment	4,297
Research and Development	129,643
Selling, General and Administrative Expense	46,849

Output Variable	Value in 1000 USD
Assets	338,021
Liabilities	34,889
Expenses	181,375
Revenues	244,061
Stockholders Equity	303,132
Net Income	87,014
Comprehensive Net Income	87,014
BaseVar	411,337
ECR before Limited Liability	401%
Economic Capital Ratio	440%